Lv4
510 积分 2023-12-06 加入
A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial
1个月前
已完结
Bevacizumab and Wound-Healing Complications
1个月前
已完结
The benefits and pitfalls of adding bevacizumab to neoadjuvant chemotherapy for advanced ovarian cancer: a meta-analysis
1个月前
已完结
A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial
1个月前
已完结
Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer
1个月前
已完结
Complete resection rate at interval debulking surgery after bevacizumab containing neoadjuvant therapy: primary objective of the ANTHALYA trial
2个月前
已完结
Ovarian cancer
2个月前
已完结
A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness
2个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
4个月前
已完结
皖公网安备34019202002308
